Cadila Launches Joint Venture With Novavax In India

Novavax and Cadila Pharmaceuticals have launched a joint venture in India, under the agreement signed between the two companies in March 2009. This joint venture CPL Biologicals, would develop and manufacture vaccines, biological therapeutics and diagnostics in India using Novavax and Cadila’ technologies.

In addition, CPL Biologicals would establish manufacturing facilities in India. They would develop and sell seasonal influenza vaccine and other vaccines against dengue fever and chikungunya fever, based on Novavax’s virus-like-particle vaccine technology.

CPL Biologicals also expects to develop the pandemic H1N1 influenza vaccine candidate in India, that Novavax is developing in the US.

I A Modi, Chairman of CPL Biologicals, said: “This joint venture represents an

important strategic alliance for vaccine development and manufacturing in India and uses unique and cutting-edge vaccine technology. Our vision is to be a leading provider of high quality, affordable vaccines, biological therapeutics and diagnostics through world-class research and innovative manufacturing to address current and future global health challenges.”